Try a new search

Format these results:

Searched for:

in-biosketch:true

person:spenck04

Total Results:

86


NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma

Cecchini, Michael; Cleary, James M; Shyr, Yu; Chao, Joseph; Uboha, Nataliya; Cho, May; Shields, Anthony; Pant, Shubham; Goff, Laura; Spencer, Kristen; Kim, Edward; Stein, Stacey; Kortmansky, Jeremy S; Canosa, Sandra; Sklar, Jeffrey; Swisher, Elizabeth M; Radke, Marc; Ivy, Percy; Boerner, Scott; Durecki, Diane E; Hsu, Chih-Yuan; LoRusso, Patricia; Lacy, Jill
BACKGROUND:Our preclinical work revealed tumour hypoxia induces homologous recombination deficiency (HRD), increasing sensitivity to Poly (ADP-ribose) polymerase inhibitors. We aimed to induce tumour hypoxia with ramucirumab thereby sensitising tumours to olaparib. PATIENTS AND METHODS/METHODS:This multi-institution single-arm Phase 1/2 trial enrolled patients with metastatic gastroesophageal adenocarcinoma refractory to ≥1 systemic treatment. In dose escalation, olaparib was evaluated at escalating dose levels with ramucirumab 8 mg/kg day 1 in 14-day cycles. The primary endpoint of Phase 1 was the recommended Phase 2 dose (RP2D), and in Phase 2 the primary endpoint was the overall response rate (ORR). RESULTS:Fifty-one patients received ramucirumab and olaparib. The RP2D was olaparib 300 mg twice daily with ramucirumab 8 mg/kg. In evaluable patients at the RP2D the ORR was 6/43 (14%) (95% CI 4.7-25.6). The median progression-free survival (PFS) was 2.8 months (95% CI 2.3-4.2) and median overall survival (OS) was 7.3 months (95% CI 5.7-13.0). Non-statistically significant improvements in PFS and OS were observed for patients with tumours with mutations in HRD genes. CONCLUSIONS:Olaparib and ramucirumab is well-tolerated with efficacy that exceeds historical controls with ramucirumab single agent for gastric cancer in a heavily pre-treated patient population.
PMID: 38135713
ISSN: 1532-1827
CID: 5611942

HCRN GI16-288: A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer-Preliminary efficacy and correlative results. [Meeting Abstract]

Spencer, Kristen Renee; Hochster, Howard S.; Boland, Patrick M.; Berim, Lyudmyla Derby; Kennedy, Timothy; Grandhi, Miral; Langan, Russell C.; Moore, Dirk F.; Kane, Michael P.; Krishnamurthi, Smitha S.; Mayo, Skye C.; Kasi, Anup; Pimentel, Agustin; Carpizo, Darren R.
ISI:001093994600209
ISSN: 0732-183x
CID: 5754862

HCRN GI16-288: A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer-Preliminary efficacy and correlative results. [Meeting Abstract]

Spencer, Kristen Renee; Hochster, Howard S.; Boland, Patrick M.; Berim, Lyudmyla Derby; Kennedy, Timothy; Grandhi, Miral; Langan, Russell C.; Moore, Dirk F.; Kane, Michael P.; Krishnamurthi, Smitha S.; Mayo, Skye C.; Kasi, Anup; Pimentel, Agustin; Carpizo, Darren R.
ISI:001093994600209
ISSN: 0732-183x
CID: 5754872

First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors [Meeting Abstract]

Ku, G.; Shen, L.; Klempner, S. J.; Pan, H.; Kratz, J.; Liang, X.; Deng, Y.; Kim, S.; Wang, Z.; Feller, L.; Powderly, J.; Dayyani, F.; Schneider, R. E.; Girda, E.; Berlin, J. D.; Spencer, K.; Nguyen, M. T.; Wang, V.; Xu, C.; Zhu, A.
ISI:001087480201369
ISSN: 0923-7534
CID: 5751532

Defining PD-L1 Expression in Gastric Cancer: How Positive is CPS for Finding and Treating the Right Patients?

Fiocco, Constance; Spencer, Kristen
(Website)
CID: 5569082

HIMALYA and IMbrave-150 for Hepatocellular Carcinoma: A Critical Comparison

Butenschoen, Henry; Spencer, Kristen
(Website)
CID: 5569072

Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma

Del Rivero, Jaydira; Perez, Kimberly; Geyer, Susan Michelle; Khalil, Maged F; Vijendran, Aishwarya; Kordaris-Corkill, Andrea; Shergill, Ardaman; Spencer, Kristen Renee; Soares, Heloisa P; Lopez, Charles D; Nixon, Andrew B; Dueck, Amylou C; Meyerhardt, Jeffrey A; O'Reilly, Eileen Mary
ORIGINAL:0017037
ISSN: 0732-183x
CID: 5569092

The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma

Pappas, Leontios; Baiev, Islam; Reyes, Stephanie; Bocobo, Andrea Grace; Jain, Apurva; Spencer, Kristen; Le, Tri Minh; Rahma, Osama E; Maurer, Jordan; Stanton, Jen; Zhang, Karen; De Armas, Anaemy Danner; Deleon, Thomas T; Roth, Marc; Peters, Mary Linton B; Zhu, Andrew X; Boyhen, Kylie; VanCott, Christine; Patel, Tushar; Roberts, Lewis R; Lindsey, Stacie; Horick, Nora; Lennerz, Jochen K; Iafrate, A John; Goff, Laura Williams; Mody, Kabir; Borad, Mitesh J; Shroff, Rachna T; Javle, Milind M; Kelley, R Katie; Goyal, Lipika
PURPOSE:Increased awareness of the distinct tumor biology for adolescents and young adults (AYAs) with cancer has led to improvement in outcomes for this population. However, in cholangiocarcinoma (CCA), a paucity of data exist on the AYA population. To our knowledge, we present the largest study to date on AYA disease biology, treatment patterns, and survival outcomes in CCA. METHODS:A multi-institutional cohort of patients with CCA diagnosed with intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma (ECC) was used for analysis. Retrospective chart review was conducted on patients who were 50 years old and younger (young; n = 124) and older than 50 years (older; n = 723). RESULTS:.049). CONCLUSION:Young patients with CCA had more advanced disease at resection, more commonly received both adjuvant and palliative therapies, and demonstrated improved survival compared with older patients. Given the low clinical trial enrollment and poor outcomes among some AYA cancer populations, data to the contrary in CCA are highly encouraging.
PMCID:10581631
PMID: 37561981
ISSN: 2473-4284
CID: 5595492

Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research

Kumar, Ritesh; Kim, Jongmyung; Deek, Matthew P; Eskander, Mariam F; Gulhati, Prateek; In, Haejin; Kennedy, Timothy; Shah, Mihir M; Grandhi, Miral S; Berim, Lyudmyla; Spencer, Kristen R; Langan, Russell C; Hochster, Howard S; Boland, Patrick M; Jabbour, Salma K
Oncological outcomes are improving in gastrointestinal cancer with advancements in systemic therapies, and there is notable potential in combining immunotherapy and radiation therapy (RT) to allow for further improvements. Various preclinical and early phase II studies have shown promising synergy with immunotherapy and RT in gastrointestinal cancer. A few recent phase III studies have shown improved survival with the addition of immunotherapy to standard treatment for gastrointestinal cancer. The timing, duration, sequencing, and integration with other anti-cancer treatments are still areas of ongoing research. We have reviewed the published and ongoing studies of the combinations of immunotherapy and RT in gastrointestinal cancers.
PMCID:10378032
PMID: 37504333
ISSN: 1718-7729
CID: 5594122

Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma

Spencer, Kristen; Pappas, Leontios; Baiev, Islam; Maurer, Jordan; Bocobo, Andrea Grace; Zhang, Karen; Jain, Apurva; De Armas, Anaemy Danner; Reyes, Stephanie; Le, Tri Minh; Rahma, Osama E; Stanton, Jennifer; DeLeon, Thomas T; Roth, Marc; Peters, Mary Linton B; Zhu, Andrew X; Lennerz, Jochen K; Iafrate, A John; Boyhen, Kylie; VanCott, Christine; Roberts, Lewis R; Lindsey, Stacie; Horick, Nora; Goff, Laura Williams; Mody, Kabir; Borad, Mitesh J; Shroff, Rachna T; Kelley, Robin Kate; Javle, Milind M; Goyal, Lipika
BACKGROUND:Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in these populations, focusing on use of adjuvant, liver-directed, targeted, and investigational therapies. METHODS:This multicenter collaboration included patients with ICC or ECC treated at 1 of 8 participating institutions. Retrospective data were collected on risk factors, pathology, treatments, and survival. Comparative statistical tests were 2-sided. RESULTS:Among 1039 patients screened, 847 patients met eligibility (ICC = 611, ECC = 236). Patients with ECC were more likely than those with ICC to present with early stage disease (53.8% vs 28.0%), undergo surgical resection (55.1% vs 29.8%), and receive adjuvant chemoradiation (36.5% vs 4.2%) (all P < .00001). However, they were less likely to undergo molecular profiling (50.3% vs 64.3%) or receive liver-directed therapy (17.9% vs 35.7%), targeted therapy (4.7% vs 18.9%), and clinical trial therapy (10.6% vs 24.8%) (all P < .001). In patients with recurrent ECC after surgery, the molecular profiling rate was 64.5%. Patients with advanced ECC had a shorter median overall survival than those with advanced ICC (11.8 vs 15.1 months; P < .001). CONCLUSIONS:Patients with advanced ECC have low rates of molecular profiling, possibly in part because of insufficient tissue. They also have low rates of targeted therapy use and clinical trial enrollment. While these rates are higher in advanced ICC, the prognosis for both subtypes of cholangiocarcinoma remains poor, and a pressing need exists for new effective targeted therapies and broader access to clinical trials.
PMCID:10323903
PMID: 37040087
ISSN: 1460-2105
CID: 5536462